Login to Your Account

Clinic Roundup

Wednesday, July 25, 2012
• Eisai Europe Ltd., of Hatfield, UK, part of Eisai Inc., presented the first clinical data for E2609, a beta-site amyloid precursor protein-cleaving enzyme (BACE) inhibitor, during oral sessions at the Alzheimer's Association International Conference 2012 in Vancouver, British Columbia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription